MAPT and Alzheimer disease: NTK has been studied in AD, where an initial decrease in β-amyloid1-42 (a-beta) was followed by an increase of total-tau (t-tau) and phosphorylated-tau-181 (p-tau), and increases in synaptic biomarkers (Ng) and those reflecting neuroinflammation, which was pronounced in a-beta-positive individuals.